Natera Statement Regarding CareDx Suit | Natera
Back to releases

Natera Statement Regarding CareDx Suit

March 26, 2019

We are aware that CareDx has filed suit in the United States District Court for Delaware, alleging infringement of U.S. patents Nos. 9,845,497 and 8,703,652. We are confident that we will prevail in this suit should it proceed and do not expect this suit to impact our commercialization plans or disrupt our operations in any way.  We are not surprised that CareDx would attempt to disrupt the imminent commercialization of Natera’s innovative organ transplant rejection test, which does not require donor genotyping, and will compete with CareDx’s older test. In recently published studies, Natera demonstrated superior analytical and clinical test performance.

 

Contacts at Natera, Inc.
Investor Relations
Mike Brophy, 650-249-9091 x1471
mbrophy@natera.com

Media Relations
Anna Czene, 818-731-2203
aczene@natera.com

Back to Top